Taxotere and vincristine inhibit the secretion of the angiogenesis-inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines

Anticancer Research

Volumn 21, Issue 4 A, 2001, Pages 2281-2286

  Avramis, I A ^a   Kwock, R ^a   Avramis, V I ^a  

^a Division of Hematology Oncology   (United States)

Author keywords

Angiogenesis; Drug resistance; Flt 17Fc chimera; Leukemia; Taxotere; VEGF; Vincristine

Indexed keywords

ASPARAGINASE; DOCETAXEL; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VINCRISTINE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN SECRETION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASPARAGINASE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL GROWTH FACTORS; HUMANS; JURKAT CELLS; LEUKEMIA, T-CELL; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; TAXOIDS; TUMOR CELLS, CULTURED; U937 CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VINCRISTINE;

EID: 0035152252     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen - A review
2. Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line
3. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation
4. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
5. Vascular endothelial growth factors and angiogenesis
6. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
7. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
8. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia
9. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
10. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
11. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: Frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production
12. Antiangiogenic strategies and agents in clinical trials
13. Cytosine arabinoside (ara-C) resistance confers crossresistance or collateral sensitivity to other classes of anti- leukemic drugs
14. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells
15. Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel
16. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)camptothecin, topotecan, and CPT- 11 studied in the mouse cornea model
17. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
18. Angiogenesis in myelodysplastic syndromes
19. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
20. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
21. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol
22. New anticancer agents in clinical development
23. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
24. Taxotere (TXR) and Vincristine (VCR) inhibit secretion of vascular endothelial growth factor (VEGF) by human leukemia T-cell lines